Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Last week, DZ Bank AG, a German lender, filed a lawsuit against Citigroup Inc. ( C - Analyst Report ) and The Royal Bank of Scotland Group plc ( RBS ) , for misrepresentation of documents while selling mortgage-backed securities (MBS). Moreover, RBS along with UBS AG ( UBS - Analyst Report ) , faced another lawsuit filed by German lender, HSH Nordbank AG over the same issue.
The lodged complaints indict banks of presenting modified documents related to the sale of over $845 million in residential mortgage-backed securities (RMBS). Notably, Citi is involved in $362 million worth of securities, while RBS involves securities worth $279 million in the DZ Bank AG case. Moreover, the HSH Nordbank case against UBS is over $150 million in bonds while the RBS suit involves $54 million.
The Allegations
The German lenders accused the banks of issuing misleading statements with omissions related to MBS and concealment of risks associated with these securities. The plaintiff claims that the documents used for offering the securities contained fraudulent statements or omissions regarding the risks associated with the investments. Misinterpretation of these risks led to the investments, which incurred losses at current levels.
The cases have been filed in the New York State Supreme Court in Manhattan and the lenders demand compensation for the damages. However, banks have refrained from commenting on the issue.
Others Facing Similar Issues
This year, similar actions have been taken against other banking majors, including JPMorgan Chase & Co. ( JPM - Analyst Report ) , HSBC Holdings Plc. ( HBC - Analyst Report ) , Bank of America Corporation ( BAC - Analyst Report ) , Morgan Stanley ( MS - Analyst Report ) and The Goldman Sachs Group Inc. ( GS - Analyst Report ) .
Legal Woes Continue
Trouble has been brewing for banks for quite sometime now owing to fraudulent representations and breach of contract tied to RMBS. Banks face several other charges related to the sale of defective mortgage securities.
Litigation overhangs have been a common problem for major U.S. banks since the financial meltdown. In effect, these lawsuits are expected to tarnish their reputation and financials over time. However, investors and other financial institutions bearing the brunt of these faulty practices are expected to be fairly compensated.
Read the full reports :
Analyst Report on JPM
Analyst Report on UBS
Analyst Report on MS
on RBS
Analyst Report on C
Analyst Report on GS
Analyst Report on BAC
Analyst Report on HBC